| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/01/2001 | DE10031839A1 Erythropoietinkonjugate Erythropoietinkonjugate |
| 02/01/2001 | CA2696819A1 Ghrelin related peptides |
| 02/01/2001 | CA2689694A1 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/01/2001 | CA2380178A1 Polypeptide dendrimers as unimolecular carriers of diagnostic imaging contrast agents, bioactive substances and drugs |
| 02/01/2001 | CA2380050A1 Materials and processes for controlled release of thioamide moiety-containing therapeutic agents by linking to thiol-containing polymers |
| 02/01/2001 | CA2379815A1 Parenteral cisplatin emulsion |
| 02/01/2001 | CA2379777A1 Isolated peptide of the horny layer and use thereof |
| 02/01/2001 | CA2378377A1 Method for releasing an agent from a red blood cell |
| 02/01/2001 | CA2378372A1 Oil-in-water emulsion with improved stability |
| 02/01/2001 | CA2377024A1 Ophthalmic composition comprising ketotifen |
| 01/31/2001 | EP1072617A1 Temperature sensitive polymers |
| 01/31/2001 | EP1072262A1 Dispersible fluoxetine tablet |
| 01/31/2001 | EP1072260A1 Transdermal systems for the release of muscarinic receptor antagonists and use thereof for treatement of smooth muscle spasms in urology |
| 01/31/2001 | EP1072256A1 Tablets quickly disintegrating in the oral cavity and process for producing the same |
| 01/31/2001 | EP1072255A2 Desferrioxamine oral delivery system |
| 01/31/2001 | EP1072252A2 Use of cosmetic or dermatologic compositions for stabilising ascorbic acid and/or its derivatives |
| 01/31/2001 | EP1071764A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN $g(a) v?-SUBUNIT EXPRESSION |
| 01/31/2001 | EP1071763A1 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates |
| 01/31/2001 | EP1071481A1 Preparation for regenerating collagen |
| 01/31/2001 | EP1071469A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor |
| 01/31/2001 | EP1071468A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 01/31/2001 | EP1071467A1 Comb copolymers for regulating cell-surface interactions |
| 01/31/2001 | EP1071466A1 Glycolipid creams |
| 01/31/2001 | EP1071465A1 Amorphous glasses for stabilising sensitive products |
| 01/31/2001 | EP1071464A2 Spray-dried powders with high edible-oil loadings based on non-hydrolyzed gelatin and a method of making such spray-dried tablettable powders |
| 01/31/2001 | EP1071460A1 INTERNALIZING ErbB2 ANTIBODIES |
| 01/31/2001 | EP1071457A1 Polymer particle vaccine delivery system |
| 01/31/2001 | EP1071455A1 Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| 01/31/2001 | EP1071448A1 Use of protease inhibitors for treating skin wounds |
| 01/31/2001 | EP1071438A2 Stabilised virus preparation |
| 01/31/2001 | EP1071432A1 Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine |
| 01/31/2001 | EP1071415A2 Flutamide compositions and preparations |
| 01/31/2001 | EP1071407A1 Lipophilic microparticles containing a protein drug or antigen and formulation comprising same |
| 01/31/2001 | EP1071403A1 Pharmaceutical composition containing a statin and aspirin |
| 01/31/2001 | EP1071400A1 Drug delivery of proteins from polymeric blends |
| 01/31/2001 | EP1071398A1 Implants for administering substances and methods of producing implants |
| 01/31/2001 | EP1071397A2 Controlled release peroral compositions of levosimendan |
| 01/31/2001 | EP1071330A1 Stabilization of isothiazolone |
| 01/31/2001 | EP0799054B1 Conjugate for treating inflammatory diseases |
| 01/31/2001 | EP0619732B1 Biodegradable polymers for cell transplantation |
| 01/31/2001 | EP0610356B1 Treatment of bacterial dysentery |
| 01/31/2001 | EP0598818B1 Escherichia coli o-polysaccharide-protein conjugate vaccine |
| 01/31/2001 | CN1282345A Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
| 01/31/2001 | CN1282334A Mitochondrially targeted antioxidants |
| 01/31/2001 | CN1282250A Progestin therapy with controlled bleeding |
| 01/31/2001 | CN1282247A Stable drug composition |
| 01/31/2001 | CN1282246A Rapidly soluble drug composition |
| 01/31/2001 | CN1282245A Molecular dispersion composition with enhanced bioavailability |
| 01/31/2001 | CN1282244A Pharmaceutical compositions |
| 01/31/2001 | CN1282240A Rate controlling membranes for controlled drug delivery device |
| 01/30/2001 | US6180666 Use of gallic acid esters to increase bioavailability of orally administered pharmaceutical compounds |
| 01/30/2001 | US6180614 Methods of immunization of aquaculture species by introducing dna expression systems into the aquaculture species |
| 01/30/2001 | US6180608 Packaged formulation for treating a subject for a condition treatable with an lhrh analogue, comprising ionic complex of lhrh analogue and carrier macromolecule |
| 01/30/2001 | US6180604 Compositions and methods for treating infections using analogues of indolicidin |
| 01/30/2001 | US6180601 Freeze-dried soft, flexible and continous matrix of hyaluronic acid containing peptide or protein used for wound healing |
| 01/30/2001 | US6180414 Breath test for detection of drug metabolism |
| 01/30/2001 | US6180389 Virion-constrained nanoparticles comprising a plant virion coat protein shell and encapsulated guest molecules |
| 01/30/2001 | US6180140 Modified amino acids for drug delivery |
| 01/30/2001 | US6180136 Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use |
| 01/30/2001 | US6180134 For treating subject with small effector molecules which are normally subject to rapid renal clearance from bloodstream; for treating septic shock, for use in treating inflammation related to neutrophil recruitment and tissue infiltration |
| 01/30/2001 | US6180114 Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
| 01/30/2001 | US6180096 Formulations for protection of peg-interferon alpha conjugates |
| 01/30/2001 | US6180095 Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| 01/30/2001 | US6180087 Tunable indocyanine dyes for biomedical applications |
| 01/30/2001 | CA2183292C Improved method of preparing polyalkylene oxide carboxylic acids |
| 01/30/2001 | CA2011637C Compositions for the sustained-release of chlorhexidine |
| 01/30/2001 | CA2011171C Biodegradable poly (phosphate esters) |
| 01/25/2001 | WO2001005991A1 Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same |
| 01/25/2001 | WO2001005968A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 01/25/2001 | WO2001005873A1 Neutral lipopolymer and liposomal compositions containing same |
| 01/25/2001 | WO2001005819A1 Novel water soluble-cyclosporine conjugated compounds |
| 01/25/2001 | WO2001005818A1 Novel water soluble-cyclosporin conjugated compounds |
| 01/25/2001 | WO2001005797A1 Titanium derived compounds, preparation and use thereof |
| 01/25/2001 | WO2001005586A1 Temperature-sensitive polymer/nanoshell composites for photothermally modulated drug delivery |
| 01/25/2001 | WO2001005434A2 Hyaluronic acid-protein conjugates |
| 01/25/2001 | WO2001005433A2 Delivery and retention of activity agents to lymph nodes |
| 01/25/2001 | WO2001005432A2 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 01/25/2001 | WO2001005431A1 Taste masking of oral quinolone liquid preparations using ion exchange resins |
| 01/25/2001 | WO2001005430A1 Sustained release drug dispersion delivery device |
| 01/25/2001 | WO2001005429A2 Powder particles with smooth surface for use in inhalation therapy |
| 01/25/2001 | WO2001005427A1 Psca: prostate stem cell antigen and uses thereof |
| 01/25/2001 | WO2001005413A1 Use of propionic bacteria for producing propionic acid and/or propionates in the colon |
| 01/25/2001 | WO2001005411A1 Compositions addressing inflammation and/or degenerative disorders |
| 01/25/2001 | WO2001005409A1 Novel spinal and epidural anaesthetic |
| 01/25/2001 | WO2001005407A1 Rapid immediate release oral dosage form |
| 01/25/2001 | WO2001005381A1 Percutaneously absorbable preparations |
| 01/25/2001 | WO2001005380A1 Sustained release compositions, process for producing the same and use thereof |
| 01/25/2001 | WO2001005379A1 BIODEGRADABLE POLY(ALKYLENE OXIDE)-POLY(p-DIOXANONE) BLOCK COPOLYMER SOLUBLE IN ORGANIC SOLVENTS, AND DRUG DELIVERY COMPOSITION COMPRISING SAME |
| 01/25/2001 | WO2001005378A1 Ambroxol-containing lozenge |
| 01/25/2001 | WO2001005374A1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/25/2001 | WO2001005373A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | WO2001005372A2 A liposome composition having resistance to freeze/thaw damage |
| 01/25/2001 | WO2001005367A1 A process for stabilizing antioxidant compounds, and aqueous compositions |
| 01/25/2001 | WO2001005362A2 Emulsifier-free finely dispersed water-in-oil-type systems |
| 01/25/2001 | WO2001005361A2 Emulsifier-free finely dispersed systems of the oil-in-water type |
| 01/25/2001 | WO2001005357A1 Two-component composition for cosmetic or pharmaceutical use |
| 01/25/2001 | WO2001005355A2 Formulations for il-11 |
| 01/25/2001 | WO2000072827A3 Porous drug matrices and methods of manufacture thereof |
| 01/25/2001 | WO2000071566A3 Novel organic anion transport proteins |
| 01/25/2001 | WO2000071095A3 Release of poorly soluble agents |